Abstract
The ability to predict and detect clinical and subclinical nephrotoxicity early in the course of therapy has the potential to improve long-term outcomes in cancer patients receiving cisplatin chemotherapy. Pharmacokinetic parameters could serve as predictors of cisplatin-induced nephrotoxicity. Participants [n = 13] were treated with a 1-h cisplatin infusion [30-75 mg/m2]. Blood was collected pre-dose and up to 6 h post-dose. Urinary biomarkers [KIM-1, calbindin, clusterin, GST-pi, β2M, albumin, NGAL, osteopontin, clusterin, MCP-1, cystatin C, and TFF3] were measured at baseline, days 3 and 10. Total and unbound platinum concentrations were measured using ICP/MS. Noncompartmental analysis was performed, and correlation and regression analyses evaluated the relationships between platinum pharmacokinetics and nephrotoxicity. Peak platinum urinary concentrations correlated with urinary levels of KIM-1, calbindin, clusterin, GST-pi, β2M, albumin, NGAL, osteopontin, clusterin, cystatin C, and TFF3 at day 10. Unbound platinum plasma concentrations at 2 h also correlated with urinary clusterin, β2M, cystatin C, NGAL, osteopontin, and TFF3 at day 3. Regression analyses suggested 2-h total plasma platinum concentrations greater than 200...Continue Reading
References
Aug 1, 1978·The American Journal of Medicine·N E Madias, J T Harrington
Feb 1, 1992·Pharmacology & Toxicology·T YasumasuJ Kumazawa
Jan 1, 1995·Journal of Cancer Research and Clinical Oncology·L J van WarmerdamJ H Beijnen
Jan 1, 1996·Cancer Chemotherapy and Pharmacology·J MaJ H Schellens
Jan 1, 1996·Cancer Chemotherapy and Pharmacology·N NagaiY Kurita
Jan 1, 1997·Cancer Chemotherapy and Pharmacology·N Nagai, H Ogata
Oct 16, 2001·European Journal of Clinical Pharmacology·B ErdlenbruchM Lakomek
Sep 19, 2003·Seminars in Nephrology·Istvan Arany, Robert L Safirstein
Mar 7, 2007·Analytical and Bioanalytical Chemistry·Ruimin XieBrian Buckley
Feb 15, 2008·Kidney International·N Pabla, Z Dong
Oct 24, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Michael HaaseUNKNOWN NGAL Meta-analysis Investigator Group
May 12, 2010·Nature Biotechnology·Frank DieterleWilliam Mattes
May 12, 2010·Nature Biotechnology·Vishal S VaidyaJoseph V Bonventre
Nov 4, 2010·Advances in Chronic Kidney Disease·Prasad Devarajan
Sep 3, 2011·American Heart Journal·Hicham SkaliScott D Solomon
Apr 12, 2012·Toxicologic Pathology·M PinchesM Moores
Aug 15, 2012·Nephron. Clinical Practice·Arif Khwaja
Sep 26, 2012·Nature Reviews. Nephrology·Michael HaaseClaudio Ronco
Sep 27, 2015·Cancer Chemotherapy and Pharmacology·Haruka ShinkeKazuo Matsubara
Feb 9, 2016·Journal of Pharmaceutical Sciences·Keizo FukushimaNobuyuki Sugioka
Dec 22, 2016·Clinical Pharmacology and Therapeutics·Blessy GeorgeLauren M Aleksunes
Citations
Mar 7, 2020·International Journal of Preventive Medicine·Mohammad Reza TamadonRaheb Ghorbani
Oct 5, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Anissa MoktefiChristophe Tournigand
Feb 9, 2021·Critical Reviews in Clinical Laboratory Sciences·Yumeng Wen, Chirag R Parikh
Mar 23, 2021·Acta Pharmacologica Sinica·Chun-Yan FangQin-Jie Weng
Feb 19, 2021·Journal of Clinical Pharmacology·Asaf LebelBradley L Urquhart
May 22, 2021·Acta Pharmacologica Sinica·Na ZhangMo Li
Nov 25, 2021·Pharmacology Research & Perspectives·Qin GongLijun Du
Nov 28, 2021·Journal of Personalized Medicine·Zulfan ZazuliGeoffrey Liu
Dec 12, 2021·Drugs·René J BoosmanRob Ter Heine